We are an international pharmaceutical company governed by a non-profit Foundation and headquartered in France.
With a strong international presence in 148 countries and a turnover of 4 billion euros in 2016, we employ over 21,000 people worldwide.
Being completely independent, we invest 25% of turnover (excluding generics) in Research and Development and use all our profits in growth.
We are specialised and driven by our constant search for innovation in five major research areas: cardiovascular diseases, cancers, diabetes, immuno-inflammatory diseases and neurodegenerative diseases, as well as by our activities in high quality generic drugs.
Currently, we have 23 drug candidates including 19 new molecular entities at various stages of clinical development. Our priorities are pathologies with high medical needs within our areas of expertise.